MW
Matthew W. Davis sold $26K of AQST stock
Matthew W. Davis, Chief Development Officer of Aquestive Therapeutics, Inc. (AQST), sold 7,197 shares of AQST stock worth $26K, per an SEC Form 4 filed Nov 16, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Nov 12, 2026, 4 days before it was made public.
AQST has moved +3.8% since the trade date, from $3.57 to $3.71 (Nov 19, 2026 close).
- Traded
- Nov 12, 2026
- Disclosed
- Nov 16, 2026
- Filing delay
- 4 days
- Price since
- +3.8%
- Role
- Chief Development Officer
- Source
- SEC Form 4